Immunoglobulin E specific for Chenopodium botrys pollen allergens (sIgE (Chenopodium botrys))

Immunoglobulin E (IgE) antibodies specific for Chenopodium botrys pollen allergens are the primary mediators of Type I hypersensitivity reactions to Jerusalem Oak pollen (StatPearls, 2023). These antibodies are produced by B cells upon sensitization to specific proteins within the pollen of Chenopodium botrys, a member of the Amaranthaceae family often cross-reactive with Chenopodium album (NCBI, 2022). Upon subsequent exposure, the allergens cross-link these specific IgE molecules bound to high-affinity receptors (FcεRI) on the surface of mast cells and basophils, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (Janeway's Immunobiology, 2017). This physiological cascade leads to clinical symptoms of seasonal pollinosis, including allergic rhinitis, conjunctivitis, and potentially the exacerbation of allergic asthma (World Allergy Organization, 2021). While general anti-IgE therapies like omalizumab target the constant region of all IgE molecules to reduce overall allergic sensitivity, specific IgE levels are primarily used as diagnostic biomarkers to guide allergen-specific immunotherapy (AIT) (PubChem, 2024). Understanding the specificity of these antibodies is crucial for precision medicine approaches in treating weed-pollen induced allergies.

Other names

Jerusalem Oak pollen-specific IgEDysphania botrys pollen-specific IgEFeathered Geranium pollen-specific IgEAnti-Chenopodium botrys IgEChenopodium botrys-specific IgE

Anti-IgE monoclonal antibodies, such as omalizumab, bind to the Cε3 domain of circulating IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (FDA, 2023). This sequestration reduces the density of receptors on effector cells and prevents allergen-induced degranulation. Conversely, allergen-specific immunotherapy (AIT) involves the controlled administration of Chenopodium botrys extracts to induce peripheral T-cell tolerance, increase IgG4 blocking antibodies, and eventually decrease the production and activity of allergen-specific IgE (Journal of Allergy and Clinical Immunology, 2020).